日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD

Velacur ACE 在诊断 MASLD 方面优于 FibroScan CAP。

Loomba, Rohit; Ramji, Alnoor; Hassanein, Tarek; Yoshida, Eric M; Pang, Emily; Schneider, Caitlin; Curry, Michael P; Afdhal, Nezam H

Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.

血清蛋白风险分层评分用于代谢功能障碍相关性脂肪性肝炎的诊断评估

Lai Michelle, Dillon Simon T, Gu Xuesong, Morhardt Tina L, Xu Yuyan, Chan Noel Y, Xiong Beibei, Can Handan, Ngo Long H, Jin Lina, Zhang Xuehong, Moreira Claudia C, Leite Nathalie C, Villela-Nogueira Cristiane A, Otu Hasan H, Schattenberg Jörn M, Schuppan Detlef, Afdhal Nezam H, Libermann Towia A

The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study

使用无创 Velacur® 区分健康志愿者和慢性肝病患者:一项可行性研究

Curry, Michael P; Tam, Edward; Schneider, Caitlin; Abdelgelil, Noha; Hassanien, Tarek; Afdhal, Nezam H

Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD

Velacur测定MASLD患者脂肪分数的方法及验证

Honarvar, Mohammad; Lobo, Julio; Schneider, Caitlin; Klein, Samuel; Smith, Gordon I; Loomba, Rohit; Ramji, Alnoor; Hassanein, Tarek; Yoshida, Eric M; Pang, Emily; Curry, Michael P; Afdhal, Nezam H

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

肝硬化消退与非酒精性脂肪性肝炎患者的临床结局改善相关。

Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M; Myers, Robert P

Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD

纤维化-4指数作为非酒精性脂肪性肝病患者死亡率和肝脏相关结局的独立预测因子

Vieira Barbosa, Joana; Milligan, Scott; Frick, Andrew; Broestl, Jeremy; Younossi, Zobair; Afdhal, Nezam H; Lai, Michelle

First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide

美国乙型肝炎一线治疗:替诺福韦阿来酚胺获批后的一项为期3年的前瞻性多中心真实世界研究

Pan, Calvin Q; Afdhal, Nezam H; Ankoma-Sey, Victor; Bae, Ho; Curry, Michael P; Dieterich, Douglas; Frazier, Lynn; Frick, Andrew; Hann, Hie-Won; Kim, W Ray; Kwo, Paul; Milligan, Scott; Tong, Myron J; Reddy, K Rajender

Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury

线粒体甘油-3-磷酸酰基转移酶的基因变异与肝损伤相关

Hakim, Aaron; Moll, Matthew; Brancale, Joseph; Liu, Jiangyuan; Lasky-Su, Jessica A; Silverman, Edwin K; Vilarinho, Silvia; Jiang, Z Gordon; Pita-Juárez, Yered H; Vlachos, Ioannis S; Zhang, Xuehong; Åberg, Fredrik; Afdhal, Nezam H; Hobbs, Brian D; Cho, Michael H

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study

美国丙型肝炎泛基因型直接抗病毒药物药物相互作用的发生率及真实世界治疗管理:一项回顾性观察研究

Curry, Michael P; Flamm, Steven L; Milligan, Scott; Tsai, Naoky; Wick, Nicole; Younossi, Zobair; Afdhal, Nezam H

Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD

循环microRNA与非酒精性脂肪性肝病致病因素的差异性关联

Ezaz, Ghideon; Trivedi, Hirsh D; Connelly, Margery A; Filozof, Claudia; Howard, Kellie; L Parrish, Mark; Kim, Misung; Herman, Mark A; Nasser, Imad; Afdhal, Nezam H; Jiang, Z Gordon; Lai, Michelle